My watch list
my.bionity.com  
Login  

Prodrugs combining macromolecular delivery systems with site-selective drug release represent a powerful strategy to increase selectivity of anticancer agents. We have adapted this strategy to develop new polymeric photosensitizer prodrugs (PPP) sensitive to urokinase-like plasminogen activator (uPA). In these compounds (to be referred to as uPA-PPPs) multiple copies of pheophorbide a are attached to a polymeric carrier via peptide linkers that can be cleaved by uPA, a protease overexpressed in prostate cancer (PCa). uPA-PPPs are non-phototoxic in their native state but become fluorescent and produce singlet oxygen after uPA-mediated activation. In the present work, we studied the influence of side-chain modifications, molecular weight, and overall charge on the photoactivity and pharmacokinetics of uPA-PPPs. An in vitro promising candidate with convertible phototoxicity was then further investigated in vivo. Systemic administration resulted in a selective accumulation and activation of the prodrug in luc...

Authors:   Maria-Fernanda Zuluaga; Doris Gabriel; Norbert Lange
Journal:   Molecular Pharmaceutics
Year:   2012
DOI:   10.1021/mp2005774
Publication date:   15-05-2012

Watchlist

This is where you can add this publication to your personal favourites.

Additional Information

Facts, background information, dossiers
More about American Chemical Society Publications
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE